A microneedle stent enables intestinal anastomosis and localized drug delivery for postoperative adjuvant therapy in resectable intestinal diseases.

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer / cancer, ESTRO, ESTRO 2025, gastric cancer, Headlines, Leong

Perioperative durvalumab plus FLOT improved overall survival versus placebo plus FLOT and is a new standard treatment option for patients with resectable gastric or gastro-oesophageal junction adenoca...

Potential predictive biomarkers of perioperative nivolumab therapy benefit in non-small cell lung cancer are identified from evaluable participants in the CheckMate 77T trial.

Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenges conventional randomized designs. We propose an MRD Registry as an external control cohort that integrates quantitative ctDNA data with outcomes to validate ctDNA dynamics as response indicators—facilitating efficient MRD-based trial design and accelerating novel therapy development.

On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally

Potential predictive biomarkers of perioperative nivolumab therapy benefit in non-small cell lung cancer are identified from evaluable participants in the CheckMate 77T trial.

MATTERHORN trial at ASCO 2025: Durvalumab + FLOT improves event-free survival in resectable gastric cancer, signaling a new standard of care.

CASSANDRA phase 3 trial shows that preoperative PAXG is superior to mFOLFIRINOX for stage I–III resectable and borderline resectable PDAC.

Immuno-chemotherapy has demonstrated significant anti-tumor effects in patients with resectable non-small cell lung cancer (NSCLC). Additionally, for patients initially diagnosed with unresectable sta...

Perioperative immunotherapy (before and after surgery) is consolidating as the new standard of treatment for locally advanced gastric and gastroesophageal junct

As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes...

Patients with biologically borderline resectable pancreatic cancer—an anatomically resectable disease with carbohydrate antigen 19-9 ≥200 U/ml, lymphadenop